5-Amino-1MQ (5-amino-1-methylquinolinium) is the most studied inhibitor of nicotinamide N-methyltransferase (NNMT) — an enzyme that acts as a metabolic brake in fat cells by depleting both SAM (S-adenosylmethionine) and NAD+ precursors.

5-Amino-1MQ (5-amino-1-methylquinolinium) is the most studied inhibitor of nicotinamide N-methyltransferase (NNMT) — an enzyme that acts as a metabolic brake in fat cells by depleting both SAM (S-adenosylmethionine) and NAD+ precursors. Unlike GLP-1 agonists that reduce appetite or growth hormone peptides that stimulate lipolysis, the compound addresses fat metabolism at the enzymatic level: it removes the molecular governor that locks adipocytes into a low-energy-expenditure state, potentially restoring normal metabolic function in fat tissue where NNMT is overexpressed.

An important clarification: this compound is technically a small molecule, not a peptide. It is a methylquinolinium derivative with a molecular weight far smaller than traditional peptides. However, it appears alongside peptides in the metabolic research space because its mechanism — NNMT inhibition that preserves NAD+ and SAM pools — intersects directly with the same cellular energy and epigenetic pathways that metabolic peptides target. PSPeptides offers research-grade 5-Amino-1MQ for laboratory studies investigating NNMT biology and adipocyte metabolism.

What Is NNMT and Why Does 5-Amino-1MQ Inhibit It?

NNMT (nicotinamide N-methyltransferase) is a cytosolic enzyme that catalyzes a specific methylation reaction: it transfers a methyl group from S-adenosylmethionine (SAM) to nicotinamide, producing two products — 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH). This reaction simultaneously depletes two critically important metabolic cofactors: SAM (the universal methyl donor for hundreds of epigenetic and biosynthetic reactions) and nicotinamide (the precursor for NAD+ biosynthesis via the salvage pathway).

NNMT becomes a metabolic problem when it is overexpressed — which is precisely what happens in obesity. Published research has demonstrated that NNMT expression is significantly elevated in white adipose tissue of obese individuals compared to lean controls. The consequences of NNMT overexpression create a metabolic feedback loop that promotes and maintains obesity. Researchers studying metabolic dysfunction in adipose tissue have identified NNMT as one of the most consistently upregulated enzymes in obese white fat, making it a high-confidence therapeutic target for metabolic intervention.

When NNMT is overactive in adipocytes, SAM is depleted — reducing the cell’s capacity for methylation reactions that regulate gene expression, including the epigenetic programs that control energy expenditure. Simultaneously, nicotinamide is consumed — reducing the substrate available for the salvage pathway to regenerate NAD+. Lower NAD+ means reduced sirtuin activity (SIRT1, SIRT3), which further impairs mitochondrial function and fatty acid oxidation in fat cells. The net effect: adipocytes become metabolically sluggish, oxidizing less fat, storing more energy, and resisting signals that would normally promote energy expenditure.

5-Amino-1MQ was specifically engineered to inhibit this enzyme. By blocking NNMT, it prevents the methylation reaction that depletes SAM and nicotinamide, thereby preserving both cofactors and restoring the metabolic machinery that NNMT overexpression had suppressed. This mechanism represents a fundamentally different approach to fat metabolism compared to appetite suppression (GLP-1 agonists) or direct lipolysis stimulation (growth hormone peptides).

What Does the Preclinical Research Show?

The foundational preclinical study was published by Neelakantan et al. in 2018 (PMID: 29155147) in Biochemical Pharmacology. This study established the core evidence that drives current research interest — and it is important to note that this is primarily a preclinical (mouse) evidence base. As of mid-2026, no published human clinical trials exist for 5-Amino-1MQ specifically.

In the Neelakantan study, diet-induced obese (DIO) C57BL/6 mice were treated with NNMT inhibitors including 5-Amino-1MQ analogues. The key findings from this published research demonstrated several important results. Treated mice showed significant reductions in body weight and white adipose tissue mass compared to untreated controls on the same high-fat diet. Plasma total cholesterol was significantly lowered in the treated group. These body composition changes occurred without any measured change in food intake — meaning the weight loss was driven by metabolic changes rather than appetite suppression. No adverse effects were reported at therapeutic doses during the study period.

Additional preclinical work published in Cell Chemical Biology evaluated NNMT inhibition in similar diet-induced obesity models and confirmed the pattern: significant reductions in body weight gain, adipose tissue expansion, and circulating triglycerides compared to untreated controls. Cell culture studies have shown that NNMT inhibition increases intracellular NAD+ levels, enhances sirtuin activity, and shifts adipocyte metabolism toward greater fatty acid oxidation.

The consistency of the preclinical data across multiple studies and laboratories supports the mechanistic hypothesis. However, translating mouse fat metabolism data to human outcomes requires substantial caution. Mice have different metabolic rates, body composition, and adipose tissue biology than humans. The 7% body weight reduction observed in mouse models may not translate proportionally to human weight loss — it could be more, less, or require entirely different dosing and duration.

The NNMT-NAD+-Sirtuin Axis: How 5-Amino-1MQ Connects to Longevity Research

The most scientifically compelling aspect of this compound is its mechanistic connection to the NAD+-sirtuin axis — the same pathway that drives the enormous research interest in NAD+ supplementation, NMN, and NR. For a complete understanding of NAD+ biology and its role in aging, see our NAD+ complete guide.

NNMT depletes the NAD+ precursor pool by methylating nicotinamide — the same nicotinamide that the salvage pathway would otherwise convert back into NAD+ via the enzyme NAMPT. When NNMT is overactive, less nicotinamide is available for recycling, and cellular NAD+ levels fall. By inhibiting NNMT, the compound preserves the nicotinamide pool, allowing the salvage pathway to maintain higher NAD+ levels without external supplementation.

This creates an interesting mechanistic distinction. NAD+ supplementation (via NAD+, NMN, or NR) addresses the NAD+ deficit by adding more precursor substrate from outside the cell. NNMT inhibition addresses the deficit by preventing the enzyme (NNMT) that wastes the precursor from inside the cell. These are complementary approaches — one increases supply, the other reduces waste. Some researchers have conceptually explored combining both strategies for potentially synergistic effects on intracellular NAD+ levels, though no published data exists for this specific combination.

The SAM preservation aspect adds another dimension. SAM is the universal methyl donor for DNA methylation, histone methylation, and hundreds of other methylation reactions that regulate gene expression. When NNMT depletes SAM in adipocytes, epigenetic regulation is disrupted — potentially locking in gene expression patterns that favor energy storage over expenditure. By preserving SAM, NNMT inhibition may restore normal epigenetic control of metabolic gene expression in fat cells. This epigenetic dimension connects the research to the broader field of metabolic epigenetics that researchers studying longevity peptides like epitalon also work in.

5-Amino-1MQ and Muscle Stem Cell Research

Beyond adipose tissue metabolism, NNMT has attracted research interest for its role in muscle stem cell (satellite cell) biology. Published studies have shown that NNMT expression affects myogenic differentiation — the process by which satellite cells activate, proliferate, and fuse to form new muscle fibers. NNMT inhibition in cell culture models has been associated with enhanced myogenic commitment, suggesting that the same NAD+/SAM preservation mechanism that restores adipocyte energy expenditure may also support muscle regeneration processes.

This finding is particularly relevant in the context of age-related muscle loss (sarcopenia) and obesity-associated muscle dysfunction. Obese individuals often exhibit both elevated NNMT in adipose tissue and impaired muscle regenerative capacity — a connection that NNMT’s dual tissue effects could help explain. By preserving NAD+ and SAM in both fat and muscle tissue, NNMT inhibition may theoretically address the metabolic dysfunction underlying both excessive fat storage and impaired muscle maintenance. For researchers studying muscle biology, our muscle growth and recovery guide covers peptides like growth hormone secretagogues and IGF-1 compounds that support muscle anabolism through receptor-mediated signaling rather than enzymatic metabolic restoration.

The connection between NNMT and muscle biology adds a body composition dimension to the research that extends beyond simple fat loss. If NNMT inhibition both restores adipocyte energy expenditure (promoting fat reduction) and supports myogenic differentiation (preserving or enhancing muscle), the net body composition effect could be recomposition — simultaneous fat loss and lean mass preservation. This contrasts with GLP-1-based weight loss, where approximately 40% of total weight lost is lean tissue. However, these body composition hypotheses are based on cell culture and animal data; human confirmation is absent.

How Does 5-Amino-1MQ Compare to Other Metabolic Research Compounds?

Understanding where the compound fits in the metabolic research landscape requires comparing its mechanism to the peptides and compounds that researchers most frequently study for body composition effects.

The critical difference is mechanism type. GLP-1-based compounds (retatrutide, semaglutide, tirzepatide) work top-down through appetite suppression and hormonal signaling. The NNMT inhibitor works bottom-up at the cellular level by addressing the enzymatic dysfunction within adipocytes themselves. GH-class peptides like CJC-1295/ipamorelin and tesamorelin promote lipolysis through hormone-sensitive lipase activation — a mechanism that depends on adequate cellular energy machinery to oxidize the mobilized fatty acids. NNMT inhibition may actually improve the adipocyte’s capacity to oxidize fat by restoring the NAD+-dependent sirtuin activity and mitochondrial function that fatty acid oxidation requires.

This mechanistic distinction means the compound could theoretically be combined with appetite-suppressing peptides for a protocol that simultaneously reduces energy intake (GLP-1) and restores adipocyte energy expenditure (NNMT inhibition) — though this remains purely theoretical without published combination data. The compound could also complement GH-class peptides by ensuring that fat cells have the metabolic machinery to oxidize the fatty acids that GH-mediated lipolysis mobilizes.

For researchers studying the broader weight loss peptide landscape, our best peptides for weight loss guide covers compounds from every receptor class, and our AOD-9604 guide covers another non-appetite-based fat metabolism compound.

5-Amino-1MQ Research Protocols and Handling

The compound is notable in the research peptide space for being orally bioavailable in animal models — most metabolic research compounds require injection. The Neelakantan et al. study used oral administration in rodents, which is part of what attracted research interest. However, human pharmacokinetic data is not published, so oral bioavailability in humans is not confirmed.

PSPeptides supplies the compound in research-grade form for laboratory investigation. Storage should follow standard protocols: store at -20°C in lyophilized form protected from light and moisture. See our peptide storage guide for comprehensive handling recommendations. For reconstitution of injectable forms, our reconstitution guide covers aseptic technique and best practices.

Researchers designing studies should carefully consider the evidence gap. Every body composition claim about the compound extrapolates from preclinical mouse data. The mechanism is well-characterized and scientifically sound — NNMT overexpression in obese adipose tissue is well-documented, and its inhibition does restore metabolic function in cell culture and animal models. But the jump from C57BL/6 mice to humans involves differences in metabolic rate, NNMT tissue distribution, adipose tissue physiology, and drug metabolism that preclinical data cannot address. Researchers should design protocols with this translational gap in mind.

Safety data is limited to the preclinical studies, where no adverse events were reported at therapeutic doses during the 11-week treatment period — the longest published study duration. However, the long-term systemic effects of chronic NNMT inhibition on methylation pathways, liver function, and cardiovascular health have not been studied. SAM is involved in hundreds of methylation reactions throughout the body, and the systemic effects of preserving SAM through NNMT inhibition in tissues beyond adipose tissue remain unknown. Researchers considering extended protocols should be aware that this safety gap exists and should monitor for unexpected effects in tissues where NNMT has normal physiological functions.

Why 5-Amino-1MQ Research Interest Is Growing

Several factors are driving increased research interest in NNMT inhibition and this compound specifically.

The success of GLP-1 agonists in clinical practice has validated the concept that pharmacological approaches to obesity are effective — but it has also highlighted their limitations. GLP-1-based compounds work primarily through appetite suppression, and the weight loss they produce includes significant lean mass loss (approximately 40% of total weight lost is lean tissue based on STEP trial data). A compound that restores adipocyte metabolism without suppressing appetite could theoretically produce fat-specific weight loss that preserves lean mass — a highly desirable outcome. For researchers studying body composition preservation, our muscle growth and recovery guide covers compounds that may complement metabolic interventions.

The connection to NAD+ biology adds another dimension of interest. As NAD+ supplementation research has expanded dramatically, the discovery that NNMT depletes NAD+ precursors specifically in metabolically dysfunctional fat tissue provides a targeted intervention point. Rather than raising NAD+ systemically (as NMN or NR supplementation does), NNMT inhibition preserves NAD+ specifically in the tissue where metabolic dysfunction is most pronounced — a precision approach that appeals to researchers studying tissue-specific metabolic regulation.

Additionally, the oral bioavailability observed in animal models makes the compound attractive for potential clinical development. Most metabolic peptides require subcutaneous injection, creating compliance barriers for chronic conditions like obesity. An orally available NNMT inhibitor — if the animal bioavailability data translates to humans — would have significant practical advantages. However, this remains a preclinical finding that has not been confirmed in human pharmacokinetic studies.

For broader context on aging biology and metabolic decline research, the NIH National Institute on Aging provides authoritative resources on the metabolic changes and epigenetic mechanisms that underlie age-associated obesity and sarcopenia.

Further Reading

For additional peer-reviewed research, see: NNMT inhibitor preclinical study by Neelakantan et al. (Biochemical Pharmacology).

Understanding 5-amino-1mq is essential for researchers navigating this rapidly evolving field in 2026.

Frequently Asked Questions

What is 5-Amino-1MQ and how does it promote fat loss?

5-Amino-1MQ is a small-molecule inhibitor of NNMT (nicotinamide N-methyltransferase), an enzyme overexpressed in obese fat tissue that depletes NAD+ precursors and SAM. By inhibiting NNMT, the compound preserves these critical cofactors, restoring sirtuin activity and normal energy expenditure in adipocytes. In preclinical mouse models, this produced significant reductions in body weight and fat mass without changes in food intake.

Is 5-Amino-1MQ a peptide?

No. 5-Amino-1MQ is a small-molecule methylquinolinium derivative, not a peptide. It appears in the peptide research space because its mechanism — NNMT inhibition affecting NAD+ and SAM pathways — intersects with the same metabolic systems that peptide researchers study. Its molecular weight is far smaller than traditional peptides.

Are there human clinical trials for 5-Amino-1MQ?

As of mid-2026, no published human clinical trials exist for the compound. The entire body composition evidence base comes from preclinical mouse studies and cell culture experiments. The mechanism is scientifically sound and consistently supported by animal data, but human efficacy and safety have not been established through clinical trials.

How does 5-Amino-1MQ relate to NAD+ supplementation?

They address NAD+ depletion from opposite sides. NAD+ supplementation (NAD+, NMN, NR) increases the supply of NAD+ precursors from outside the cell. The compound prevents NNMT from wasting nicotinamide (an NAD+ precursor) inside the cell. These approaches are mechanistically complementary — one adds substrate, the other prevents its degradation.

All PSPeptides products are sold exclusively for research and laboratory use.